This HTML5 document contains 75 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n16http://www.rxlist.com/cgi/generic3/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00247/identifier/wikipedia/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00247/identifier/pharmgkb/
n20http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n17http://linked.opendata.cz/resource/drugbank/company/
n23http://linked.opendata.cz/resource/mesh/concept/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00247/identifier/kegg-compound/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00247/identifier/bindingdb/
n26http://bio2rdf.org/drugbank:
n13http://linked.opendata.cz/resource/drugbank/drug/DB00247/identifier/kegg-drug/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00247/identifier/iuphar/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00247/identifier/drugbank/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00247/identifier/guide-to-pharmacology/
admshttp://www.w3.org/ns/adms#
n14http://linked.opendata.cz/resource/drugbank/drug/DB00247/identifier/national-drug-code-directory/
n28http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
n22http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://linked.opendata.cz/resource/drugbank/drug/DB00247/identifier/chebi/
n24http://linked.opendata.cz/resource/atc/
n19http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00247
rdf:type
n3:Drug
n3:description
An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the carcinoid syndrome. [PubChem]
n3:group
approved
n3:indication
For the treatment of vascular headache
n3:manufacturer
n17:271B6500-363D-11E5-9242-09173F13E4C5
owl:sameAs
n26:DB00247 n28:DB00247
dcterms:title
Methysergide
adms:identifier
n7:584020 n8:DB00247 n9:50031942 n10:134 n11:C07199 n12:134 n13:D02357 n14:0078-0058-05 n18:PA164743265 n21:Methysergide
n3:mechanismOfAction
Methysergide is serotonin antagonists acts on central nervous system (CNS), which directly stimulates the smooth muscle leading to vasoconstriction. Some alpha-adrenergic blocking activity has been reported. Suggestions have been made by investigators as to the mechanism whereby Methysergide produces its clinical effects, but this has not been finally established, although it may be related to the antiserotonin effect.
n3:packager
n17:271B64FE-363D-11E5-9242-09173F13E4C5 n17:271B64FF-363D-11E5-9242-09173F13E4C5 n17:271B64FD-363D-11E5-9242-09173F13E4C5
n3:synonym
1-Methyl-dextro-lysergic acid (+)-1-hydroxy-2-butylamide N-(1-(Hydroxymethyl)propyl)-1-methyl-dextro-(+)-lysergamide Metisergido 1-Methyllysergic acid butanolamide (+)-N-(1-(Hydroxymethyl)propyl)-1-methyl-D-lysergamide 1-Methylmethylergonovine 9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8-carboxamide Metisergida 1-Methyl-D-lysergic acid butanolamide Methysergidum (+)-9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8beta-carboxamide Methysergide
n3:toxicity
Few cases of acute methysergide intoxication have been reported. The possible symptom complex is therefore not fully known. The following symptoms are based on these few case reports. Euphoria, hyperactivity, tachycardia, dilated pupils, and dizziness have been reported in a child with a dose of 20-24 mg of methysergide. In adults, peripheral vasospasm, with diminished or absent pulses, coldness, mottling and cyanosis, has been observed at a dose of 200 mg. Ischemic tissue damage has not been reported in acute overdosage with methysergide.
n19:hasAHFSCode
n20:12-16-00
n3:foodInteraction
Take with food to reduce irritation.
n3:salt
n22:hasConcept
n23:M0013673
foaf:page
n16:sansert.htm
n3:IUPAC-Name
n4:271B6507-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B650D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B650C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B6509-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B650A-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B650B-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B6505-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B6503-363D-11E5-9242-09173F13E4C5 n4:271B6506-363D-11E5-9242-09173F13E4C5 n4:271B651E-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B6504-363D-11E5-9242-09173F13E4C5
n19:hasATCCode
n24:N02CA04
n3:H-Bond-Acceptor-Count
n4:271B6513-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B6514-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B650E-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B650F-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B6511-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B6510-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B6512-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapid
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
361-37-5
n3:category
n3:containedIn
n5:271B6501-363D-11E5-9242-09173F13E4C5 n5:271B6502-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B6519-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B651B-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B651C-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B651D-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B6518-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B6517-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B651A-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B6508-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B6515-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B6516-363D-11E5-9242-09173F13E4C5